Konstantin Walmsley

Columbia University, New York, New York, United States

Are you Konstantin Walmsley?

Claim your profile

Publications (4)10.88 Total impact

  • Steven A Kaplan, Konstantin Walmsley, Alexis E Te
    [Show abstract] [Hide abstract]
    ABSTRACT: In this open label, prospective study we determined the efficacy and tolerability of tolterodine extended release (ER) in men with benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) in whom previous alpha-blocker therapy had failed. A total of 43 consecutive men with BPH and LUTS in whom a mean of 5.7 months of alpha-blocker therapy had failed due to adverse events (11) or a lack of efficacy (32) received tolterodine ER (4 mg daily) for 6 months. Primary efficacy end points were American Urological Association symptom score, and mean daytime and nighttime micturition frequency. Secondary end points were the peak urinary flow rate, post-void residual volume, the incidence of urinary retention, total score on the erectile function domain of the International Index of Erectile Function and adverse events. A total of 39 men (91%) with a mean age of 61 years completed the 6-month trial. Mean 24-hour micturition frequency decreased from 9.8 to 6.3 voids and nocturia decreased from 4.1 to 2.9 episodes nightly. Significant changes in mean American Urological Association symptom scores (-6.1), the peak urinary flow rate (1.9 ml per second) and post-void residual volume (-22 ml) were also observed. Of the men 27 (63%) were potent at baseline and 29 (67%) were potent after 6 months of tolterodine ER treatment. Mean International Index of Erectile Function erectile function domain scores increased (6.9). Four men (9%) discontinued therapy because of intolerable dry mouth. There were no reports of urinary retention. Treatment with tolterodine ER in men with BPH and LUTS may be a reasonable therapeutic option as initial therapy or after failed treatment with alpha-blockers.
    The Journal of urology 06/2008; 179(5 Suppl):S82-5. DOI:10.1016/j.juro.2008.03.142 · 3.75 Impact Factor
  • Source
    Carl K Gjertson, Konstantin Walmsley, Steven A Kaplan
    [Show abstract] [Hide abstract]
    ABSTRACT: Our treatment strategies for benign prostatic hyperplasia (BPH) have changed, with new insights into the pathophysiology of the disease, new clinical trials, and surgical advances. We present an update on treatment options and a diagnostic and treatment algorithm for this condition.
    Cleveland Clinic Journal of Medicine 12/2004; 71(11):857, 860, 863-5 passim. DOI:10.3949/ccjm.71.11.857 · 3.37 Impact Factor
  • Konstantin Walmsley, Steven A Kaplan
    [Show abstract] [Hide abstract]
    ABSTRACT: Transurethral microwave thermotherapy (TUMT) is being used with increasing frequency by urologists as a minimally invasive therapy for benign prostatic hyperplasia (BPH). There are various modifications to this technology, with each manufacturer touting safety and efficacy. We review the rationale of TUMT, as well as the historical safety and efficacy of this approach. We reviewed the medical literature, including peer reviewed articles and abstracts. In addition, we analyzed promotional material distributed by various manufacturers with respect to scientific accuracy. TUMT results in consistent improvement in symptoms and peak urinary flow rate. Symptom improvement ranges between 9 and 11 points, compared to a 6-point improvement in sham treated patients, and peak urinary flow rate increases 3 to 5 ml per second. The degree of coagulation necrosis is different among the various TUMT devices. Although coagulation necrosis is believed to be an important proxy for clinical success, there are few data that correlate this factor with the magnitude of either symptomatic or uroflow improvement. TUMT is a safe and effective therapy for the treatment of lower urinary tract symptoms secondary to BPH. In addition, there are distinct advantages to each of the devices. However, intense marketing and hyperbole have dominated this segment of the BPH market. Ultimately, the most effective TUMT device can only be determined by direct comparison studies.
    The Journal of Urology 11/2004; 172(4 Pt 1):1249-55. DOI:10.1097/01.ju.0000163565.38631.40 · 3.75 Impact Factor